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Aim. To evaluate the impact of hepatitis B core antibody (anti-HBc) seropositivity in sustained virological response (SVR)
rates in treatment-na¨ ıve, chronic hepatitis C (CHC) patients with high pretreatment viral load (>800000IU/mL). Methods. 185
consecutive CHC patients (14.4% cirrhotics, 70.2% prior intravenous drug users) treated with pegylated interferon-a2b plus
ribavirin, for 24 or 48 weeks based on viral genotype, were retrospectively analyzed. SVR was conﬁrmed by undetectable serum
HCV-RNA six months after the end of treatment schedule. Results. Thirty percent of CHC/HBsAg-negative patients were anti-
HBc-positive. Anti-HBc positivity was more prevalent in cirrhotic, compared to noncirrhotic patients (76.9% versus 19.5%,
P<. 05). Serum HBV-DNA was detected in the minority of anti-HBc-positive patients (1.97%). Overall, 62.1% of patients
exhibited SVR, while 28.6% did not; 71.4% of non-SVRs were infected with genotype 1. In the univariate analysis, the anti-HBc
positivity was negatively associated with treatment outcome (P = .065). In the multivariate model, only the advanced stage of
liver disease (P = .015) and genotype-1 HCV infection (P = .003), but not anti-HBc-status (P = .726), proved to be independent
predictors of non-SVR. Conclusion. Serum anti-HBc positivity does not aﬀect the SVR rates in treatment-na¨ ıve CHC patients with
high pretreatment viral load, receiving the currently approved combination treatment.
Copyright © 2009 Ioannis S. Elefsiniotis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The combination of interferon-alpha (IFNa) and ribavirin
(RIB) produced response rates in approximately 40% of
previously untreated patients with chronic hepatitis C [1,
2]. Pegylated interferon-alpha (PEG-IFNa) plus ribavirin is
currently the treatment of choice in patients with chronic
hepatitis C virus- (HCV-) related liver disease [3, 4]. Viral
genotype, pretreatment viral load as well as patient age, body
weight, and liver histopathology are important predictors of
response according to landmark trials [4–7].
Hepatitis B virus (HBV) and HCV share the same routes
of transmission but the vast majority of acutely infected
patients recover spontaneously from HBV infection, whereas
they become chronically infected by HCV, due to the diﬀer-
ent natural course of the viral infections [3, 8]. The clinical
impact of occult HBV infection, deﬁned as the presence
of serum HBV-DNA in the absence of hepatitis B surface
antigen (HBsAg) and its high prevalence in chronic HCV-
infected patients has been documented by several studies [9–
12]. Nevertheless, the signiﬁcance of occult hepatitis B in
terms of response to currently approved antiviral treatment
of chronic hepatitis C patients, especially those with high
pretreatment HCV viral load, remains controversial [13–16].
The principal aim of our study was to evaluate the
impact of anti-HBc seropositivity on the sustained viro-
logical response rates in treatment-na¨ ıve chronic hepatitis
C patients with high pretreatment viral load, treated with
PEG-IFNa2b plus RIB under real life conditions in Greece.
Also, we intended to investigate the prevalence of detectable
HBV-DNA in serum of anti-HBc-positive chronic hepatitis
C patients of the study population.2 Gastroenterology Research and Practice
2.MaterialandMethods
Two referral centers for chronic viral hepatitis in Greece
participated in this study. One hundred eighty-ﬁve con-
secutive treatment-na¨ ıve patients with chronic hepatitis C
(CHC) with available data from medical records from 2000
to 2007 were retrospectively analyzed. Inclusion criteria were
detectable anti-HCV (ELISA III) at least two times within
a year, detectable HCV-RNA in serum with a sensitive
PCR assay and high pretreatment viral load (HCV-RNA
> 800IU/mL) within a month before the beginning of
treatment, schedule, liver biopsy indicating chronic hepatitis
within 6 months before treatment and elevated alanine
aminotransferace (ALT) activity before treatment (>40IU/L
and <400IU/L) and at least once during the last 6 months.
Exclusion criteria were decompensated liver disease,
chronic liver disease of any other cause other than chronic
HCV infection, and alcohol abuse (deﬁned as consuming
more than 30 gram alcohol per day for at least 5 years).
Patients with HIV infection as well as active substance abuse
were also excluded.
All patients had been evaluated on admission clinically,
hematologically, biochemically, and serologically, using rou-
tine commercially available methods. All participants of the
study had their height and weight recorded at the beginning
of the study, and their body mass index (BMI) had been
calculated by dividing patient’s weight (kg) by the squared
height (m2). Serum HCV-RNA levels had been measured by
a commercially available polymerase chain reaction (PCR)
assay (Cobas Amplicor HCV test, version 2, Roche Diag-
nostics, Branchburg, NJ, USA) qualitatively (lower detection
limit of 50IU/mL) and quantitatively (range of detec-
tion 600–800IU/mL). HCV genotype was performed using
INNOLIPA HCV assay (Innogenetics, Belgium). Baseline
stored serum samples of anti-HBc-positive patients of our
study population were used in order to detect HBV-DNA,
using a sensitive (lower limit of detection: 400copies/mL),
commercially available, PCR assay (Amplicor, HBV Monitor,
Roche).
Liver biopsy had been performed at baseline; all biopsy
specimens were evaluated by two experienced hepatopathol-
ogist and scored according to Ishak scoring system (grade =
0–18, stage = 0–6) [17].
All patients were treated with weight-based dosing of
pegylated interferon-a2b (Peg-Intron, 1.5μg/kg/week) and
genotype-based ribavirin dose (Rebetol, 800mg/day for
genotype 2/3 and 1000–1200mg/day for genotype 1/4-
infected patients, according to baseline body weight - < or
≥85kg, resp.). The duration of treatment was 24 weeks for
genotype 2/3-infected patients and 48 weeks for genotype
1/4-infected ones.
Serum HCV-RNA data were available before the initia-
tion of treatment (qualitative and quantitative PCR assay)
and six months after the end of treatment schedule (quali-
tative PCR assay). Sustained virological response (SVR) was
conﬁrmed by undetectable serum HCV-RNA six months
aftercompletionoftreatment.Patientswithdetectableserum
HCV-RNA six months after treatment discontinuation were
characterized as non-SVRs.
Table 1: Epidemiological, serological, virological, and histological
baseline data of the study population. IVDU: intravenous drug
users; HCV: hepatitis C virus; Anti-HBc: antibody against Hepatitis
B core antigen.
Gender (male/female) 124/61
Greeks (%) 82.7
Non-Greeks (%) 17.3
IVDU (%) 70.2
HCV genotype-1 (%) 47.6
HCV genotype-2 (%) 3.6
HCV genotype-3 (%) 36.3
HCV genotype-4 (%) 12.5
Cirrhosis (%) 14.4
Anti-HBc-negative (%) 70
Anti-HBc-positive (%) 30
 Anti-HBs positive (%)  84.3
 HBV-DNA negative (%)  98.03
2.1. Statistical Analyses. The association of each genotype
group with continuous variables was investigated with either
ANOVA (using post-hoc Scheﬀe’s test when omnibus test
was signiﬁcant) or Student’s t-test. The association of each
genotype group with categorical variables was explored with
chi-square analyses. The association of SVR with continuous
variables was investigated with Student’s t-test and with
categorical variables with chi-square analyses.
We used logistic regression analyses with SVR as the
dichotomous dependent variable. In multivariate modes,
in addition to genotype variable (which was consider the
main predictor) we simultaneously included to the logistic
regression patient’s age, gender, BMI, anti-HBc serological
status, grade and stage of liver disease. In order to further
investigate possible age eﬀects in the impact of the proposed
predictors of SVR, we recalculated the logistic regression
models, categorizing the patients of our study population
with available data in three subgroups (<35 years/n = 54,
35–55 years/n = 75, >55 years/n = 56).
Local Hospital Institutional Review Board reviewed and
approved this project. The study conformed to the ethical
guidelines of the 1975 Declaration of Helsinki. Written
informed concern of the study population was not necessary
because this retrospective study did not modify the existing
diagnosis or the therapeutic strategy.
3. Results
Epidemiological, serological, virological, and histological
data of our study population are presented in Table 1.
Low-grade HBV viremia (1280copies/mL) was detected in
one anti-HBc-positive/anti-HBs-negative cirrhotic patient
(1.97% of the anti-HBc-positive study population). It is
important to note that among 26 cirrhotic patients, 20
(76.9%) were anti-HBc-positive, whereas among 159 non-
cirrhotic ones only 31 (19.5%) were anti-HBc-positive (P<
.0005, x2 = 32.593).Gastroenterology Research and Practice 3
Table 2: Comparison of clinical, serological, virological, and histo-
logical baseline data among SVRs and non-SVRs. SVR: sustained
virological response; BMI: body mass index; Anti-HBc: antibody
against Hepatitis B core antigen (∗), P<. 05.
SVRs non-SVRs
n = 115 n = 53
Age (years) 37.69 ±11.04 50.28 ±13.35 (∗)
Gender (male/female) 73/42 34/19
BMI 24.51 ±3.29 25.29 ±3.17
Genotype 1 (n, %) 42 (36.5%) 38 (71.7%) (∗)
Genotype non-1 (n, %) 73 (63.5%) 15 (28.3%) (∗)
Grade (0–18) 5.41 ±1.77 5.75 ±2.02
Stage (0–6) 1.98 ±1.12 3.33 ±1.63 (∗)
Anti-HBc (+/−) 30/85 21/32
Table 3: Multivariate analysis results. (∗), P<. 05; BMI: body mass
index; Anti-HBc: antibody against Hepatitis B core antigen.
Odds ratio (95% CI) P-value
Gender 1.519 (0.573–4.028) 0.401
Age 0.958 (0.916–1.001) 0.055
BMI 1.060 (0.911–1.232) 0.451
Genotype
(1 versus non-1)
3.550 (1.471–8.565) 0.003 (∗)
Grade 1.193 (0.921–1.545) 0.181
Stage 0.625 (0.410–0.952) 0.015 (∗)
Anti-HBc 1.192 (0.446–3.188) 0.726
One hundred sixty-eight patients (90.8% of the study
population) tolerated well and ﬁnished the treatment
schedule, while seventeen patients discontinued treatment.
One hundred ﬁfteen patients (62.1%) exhibited SVR, and
53 (28.6%) were characterized as non-SVRs. Among 115
patients with SVR, 85 (73.8%) were anti-HBc-negative,
whereas among 53 non-SVRs, 32 (60.3%) were anti-HBc-
negative.
Clinical, serological, virological, and histological baseline
data of the SVRs and non-SVRs groups are presented in
Table 2. Overall, SVR was positively related to the presence
of genotype non-1 HCV infection (P<. 0001). In particular,
compared to a genotype-1 infected patient, a patient infected
with genotype 2, 3 or 4 of HCV had 4.72, 4.82 or 1.89
more chances of achieving an SVR, respectively. SVRs
were younger (P<. 0001) and had lower histological
ﬁbrosis scores (P<. 0001), compared to non-SVRs. In the
univariate analysis, we found a signiﬁcant trend (30/115
versus 21/53, P = .057) in relationship between the anti-HBc
seropositivity and the presence of non-SVR.
Using logistic regression analysis, in the multivariate
model, adjusted for all baseline parameters, we found that
only the advance histological stage of liver disease (P =
.015) and the presence of genotype-1 HCV infection (P =
.003)wereindependentpredictorsofnon-SVR,whereasBMI
(P = .451), anti-HBc seropositivity (P = .726) as well as
patients age (P = .055) were not (Table 3), even taking into
Table 4: Comparison of clinical and histological baseline data
among anti-HBc positive and anti-HBc negative chronic hepatitis
C patients; anti-HBc: antibody against Hepatitis B core antigen.
Anti-HBc Anti-HBc P-value
positive negative
Age (years, median) 44.5 37 <.001 (∗)
BMI 25.3 24.7 .873
Grade (0–18, median) 5 5 .428
Stage (0–6, median) 3 2 .005 (∗)
Cirrhosis (n/%) 20 (76.9%) 6 (23.1%) <.0005 (∗)
(∗), P<. 05.
consideration the age subgroups (<35 years; P = .151, 35–55
years; P = .441, >55 years; P = .058). For patients younger
than 35 years old (88.7% of whom exhibited SVR) none of
the baseline parameters—neither viral genotype (P = .284),
nor the stage of liver disease (P = .351)—was independent
predictor of non-SVR, whereas for patients between 35–55
years old, only the presence of genotype-1 infection was
independently predicted non-SVR (P = .008). Additionally,
for patients older than 55 years only the advance histological
stage of liver disease (P = .047), but not HCV genotype
(P = .275), was independently predicted non-SVR (41.7%
of them exhibited SVR).
The majority of patients younger than 35 years old
(85.4%) were anti-HBc negative, whereas the corresponding
percentages for patients 35–55 years old and for patients
older than 55 years were 61.8% and 61.4%, respectively.
Table 4 summarizes the clinical and histological data among
anti-HBc-negative and anti-HBc-positive chronic hepatitis
C patients. As we can see from this table, anti-HBc-positive
patientswereolderandhadsigniﬁcantlymoreadvancedliver
disease compared to anti-HBc-negative patients. Patient’s
age had not had an impact on the eﬀect of the anti-HBc
seropositivity in the prediction of the SVR (<35 years-P =
.999, 35–55 years-P = .721, >55 years-P = .815), in the
multivariate model that was adjusted for all the baseline
parameters.
4. Discussion
The main ﬁnding of our study is that in treatment-na¨ ıve
CHC patients with high pretreatment viral load, receiving
the currently approved treatment, the advanced histological
stage of liver disease and the genotype 1 infection are nega-
tively associated with SVR achievement. Contrariwise, other
baseline parameters, including the anti-HBc seropositivity,
do not have impact on antiviral therapy outcome.
Several studies suggest that the presence of detectable
HBV-DNA in serum of HBsAg-negative/anti-HBc-positive
patients correlates with the anti-HCV positivity [14, 18],
especially in isolated anti-HBc-positive CHC patients [19]
and immunocompromised individuals, such as IVDUs [15].
Moreover, it is suggested that there is an inverse correlation
between the evolution of HBV-DNA and HCV-RNA levels
[20]. The anti-HBc-only serology seems to represent three4 Gastroenterology Research and Practice
settings: ﬁrst, false positive results with negative HBV DNA;
second,recoveryfromapreviousinfectionwithundetectable
anti-HBs titers; third, occult HBV infection. The most
probableexplanationforisolatedanti-HBcreactivityinCHC
patients with occult HBV infection is considered to be the
possible interference of HCV on HBsAg synthesis [19]. In
our study, we investigated the prevalence of serum HBV-
DNA positivity in HBsAg-negative/anti-HBc-positive CHC
patients, with or without the presence of antiHBs, and
we found that only 1.97% of them exhibited detectable,
low-grade, serum HBV-DNA. Our patients exhibited high
pretreatment HCV-RNA (>800IU/mL) levels, a parameter
that could possibly have a signiﬁcant impact in serum HBV-
DNA levels. Moreover, more than 70% of patients in our
cohort were prior IVDUs, a special group that has been
frequently involved in occult HBV infection cases [14, 15]
but only 15.6% of studied patients exhibited isolated positive
anti-HBc status. The majority of them presented anti-HBc
and anti-HBs seropositivity probably due to spontaneously
resolved acute HBV infection in the past. This represents the
commonserologicalpatternofHBVinfectionamongIVDUs
with CHC in Greece [21]. In IVDUs with CHC, HBV-DNA
is more frequent detected in liver tissue specimens (29.4%)
than in patient’s serum samples (1.9%), a ﬁnding that does
not seem to aﬀect their liver histopathology or the treatment
outcome [15].
Anti-HBc positivity was not related to virological-
conﬁrmed occult HBV infection in the vast majority of
the CHC patients of our study. This is in accordance with
the study of Haushofer et al. [22], which reported the
absenceofdetectableserumHBV-DNAinisolatedanti-HBc-
positive patients with or without CHC. Moreover, anti-HBc
seropositivitywasnotassociatedwiththetreatmentoutcome
in the multivariate model after adjustment for the entire
baseline parameters, despite a relatively signiﬁcant trend
that was observed in the univariate analysis. This trend was
probably observed due to signiﬁcant proportion of cirrhotic
patients with positive anti-HBc. Previous HBV infection was
linked to the advanced stage of liver disease, despite the low
prevalence of occult HBV infection [23], data similar to our
results.
We studied a population relatively diﬃcult to manage—
with high pretreatment viral load and genotype-1 infection
in about half of them, treated under real life conditions.
Despite that, the overall SVR rates were comparable with the
correspondingratesofthepivotaltrials[4–6].Severalstudies
suggestthatdosereductionandparticularlyprematuretreat-
mentdiscontinuationareassociatedwithamarkedreduction
of SVR rates [24, 25]. In our study, the adherence to
treatment was more than 90%, and this could possibly have a
substantial positive impact on the SVR rates. BMI was not an
important predictor of response, as proposed [26], possibly
becauseallpatientsweretreatedwithweight-adjusteddoseof
pegylated-interferon a2b. Additionally, as shown in Table 1,
the mean BMI of patients was 25, indicating that our cohort
did not include obese subjects. Additionally, we found that
the impact of the classical proposed predictors of SVR,
such as viral genotype and liver histopathology, is modiﬁed
accordingtopatient’sage.Thisﬁndingsuggeststhatalthough
the patient’s age is not an independent predictor of the SVR
achievement and other baseline parameters also should be
taken into account in our everyday clinical practice in order
to predict an SVR.
Limitations of our study are the retrospective analysis of
data, the lack of on-treatment or end of treatment virological
data, and the absence of HBV histological data from patient’s
liver tissue or serum HBV-DNA data of anti-HBc-negative
chronic hepatitis C patients. Also, it should be mentioned
that the sensitivity of the assay, used in our study for the
quantiﬁcation of HBV-DNA, is 400copies/mL. Nested PCR,
which is reported to be most sensitive, is not available in
our institution. Finally, up to 20% of individuals with occult
hepatitis B are negative for all markers of past HBV infection
aside from HBV DNA [27]. So, some cases of occult hepatitis
B possibly have been missed in our trial.
Despitetheselimitations, webelievethattheinformation
from observational studies adds a pragmatic ﬂavor of “real
life data”, an aspect often missing from clinical trials. Also,
it provides a basis for further research, so that preliminary
observations, like that of our study, could be veriﬁed or
falsiﬁed in prospective randomized control trials.
In conclusion, anti-HBcore seropositivity does not aﬀect
the SVR achievement rate in treatment-na¨ ıve CHC patients
with high pretreatment viral load, receiving a currently
approved combination treatment under “real life” condi-
tions.
References
[1] J. G. McHutchison, S. C. Gordon, E. R. Schiﬀ, et al.,
“Interferon alpha-2b alone or in combination with ribavirin
as initial treatment for chronic hepatitis C. Hepatitis Interven-
tional Therapy Group,” The New England Journal of Medicine,
vol. 339, no. 21, pp. 1485–1492, 1998.
[ 2 ]M .Y .L a i ,J .H .K a o ,P .M .Y a n g ,e ta l . ,“ L o n g - t e r me ﬃcacy
of ribavirin plus interferon alpha in the treatment of chronic
hepatitis C,” Gastroenterology, vol. 111, no. 5, pp. 1307–1312,
1996.
[3] National Institutes of Health, “NIH consensus statement on
management of hepatitis C: 2002,” NIH Consensus and State-
of-the-Science Statements, vol. 19, no. 3, pp. 1–46, 2002.
[4] S. J. Hadziyannis, H. Sette Jr., T. R. Morgan, et al.,
“Peginterferon-α2a and ribavirin combination therapy in
chronichepatitisC:arandomizedstudyoftreatmentduration
and ribavirin dose,” Annals of Internal Medicine, vol. 140, no.
5, pp. 346–355, 2004.
[ 5 ]M .P .M a n n s ,J .G .M c H u t c h i s o n ,S .C .G o r d o n ,e ta l . ,
“Peginterferon alpha-2b plus ribavirin compared with inter-
feron alpha-2b plus ribavirin for initial treatment of chronic
hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286,
pp. 958–965, 2001.
[6] M.W .F ried,M.L.Shiﬀman,K.R.Reddy,etal.,“Peginterferon
alpha-2aplusribavirinforchronichepatitisCvirusinfection,”
TheNewEnglandJournalofMedicine,vol.347,no.13,pp.975–
982, 2002.
[7] E. J. Heathcote, M. L. Shiﬀman, W. G. E. Cooksley, et al.,
“Peginterferon alpha-2a in patients with chronic hepatitis C
and cirrhosis,” The New England Journal of Medicine, vol. 343,
no. 23, pp. 1673–1680, 2000.Gastroenterology Research and Practice 5
[8] D. Ganem and A. M. Prince, “Hepatitis B virus infection—
natural history and clinical consequences,” The New England
Journal of Medicine, vol. 350, no. 11, pp. 1118–1129, 2004.
[9] I. Chemin and C. Tr´ epo, “Clinical impact of occult HBV
infections,” Journal of Clinical Virology, vol. 34, supplement 1,
pp. S15–S21, 2005.
[10] C.-K. Hui, E. Lau, H. Wu, et al., “Fibrosis progression
in chronic hepatitis C patients with occult hepatitis B co-
infection,” Journal of Clinical Virology, vol. 35, no. 2, pp. 185–
192, 2006.
[11] R. Fukuda, N. Ishimura, M. Niigaki, et al., “Serologically silent
hepatitis B virus co-infection in patients with hepatitis C
virus-associated chronic liver disease: clinical and virological
signiﬁcance,” Journal of Medical Virology,v o l .5 8 ,n o .3 ,p p .
201–207, 1999.
[12] F. Vitale, F. Tramuto, A. Orlando, et al., “Can the serological
status of “anti-HBc alone” be considered a sentinel marker
for detection of “occult” HBV infection?” Journal of Medical
Virology, vol. 80, no. 4, pp. 577–582, 2008.
[13] E. Sagnelli, N. Coppola, C. Scolastico, A. R. Mogavero, P.
Filippini, and F. Piccinino, “HCV genotype and “silent” HBV
co-infection: two main risk factors for a more severe liver
disease,” Journal of Medical Virology, vol. 64, no. 3, pp. 350–
355, 2001.
[ 1 4 ]I .C a c c i o l a ,T .P o l l i c i n o ,G .S q u a d r i t o ,G .C e r e n z i a ,M .E .
Orlando,andG.Raimondo,“OcculthepatitisBvirusinfection
in patients with chronic hepatitis C liver disease,” The New
England Journal of Medicine, vol. 341, no. 1, pp. 22–26, 1999.
[15] P. Fabris, D. Brown, G. Tositti, et al., “Occult hepatitis B virus
infection does not aﬀect liver histology or response to therapy
with interferon alpha and ribavirin in intravenous drug users
with chronic hepatitis C,” Journal of Clinical Virology, vol. 29,
no. 3, pp. 160–166, 2004.
[16] V.Carre˜ no ,J .Bartolom´ e,I.Castillo,andJ.A.Quiroga,“Occult
hepatitis B virus and hepatitis C virus infections,” Reviews in
Medical Virology, vol. 18, no. 3, pp. 139–157, 2008.
[17] K. Ishak, A. Baptista, L. Bianchi, et al., “Histological grading
and staging of chronic hepatitis,” Journal of Hepatology, vol.
22, no. 6, pp. 696–699, 1995.
[18] C. Drosten, T. Nippraschk, C. Manegold, et al., “Prevalence of
hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative
sera correlates with HCV but not HIV serostatus,” Journal of
Clinical Virology, vol. 29, no. 1, pp. 59–68, 2004.
[19] B. Weber, W. Melchior, R. Gehrke, H. W. Doerr, A. Berger,
and H. Rabenau, “Hepatitis B virus markers in anti-HBc only
positive individuals,” Journal of Medical Virology, vol. 64, no.
3, pp. 312–319, 2001.
[20] E. Khattab, I. Chemin, I. Vuillermoz, et al., “Analysis of
HCV co-infection with occult hepatitis B virus in patients
undergoing IFN therapy,” Journal of Clinical Virology, vol. 33,
no. 2, pp. 150–157, 2005.
[21] I. S. Elefsiniotis, K. D. Pantazis, I. D. Ketikoglou, S. I.
Koutsounas, and E. V. Tsianos, “Changing serological status
and low vaccination-induced protection ratesagainst hepatitis
B characterize chronic hepatitis C virus-infected injecting
drugusersinGreece:needforimmunizationpolicy,”European
Journal of Gastroenterology & Hepatology, vol. 18, no. 11, pp.
1227–1231, 2006.
[22] A. C. Haushofer, R. Hauer, H. Brunner, et al., “No evidence of
hepatitis B virus activity in patients with anti-HBc antibody
positivity with or without anti-hepatitis C virus antibody
positivity,” Journal of Clinical Virology, vol. 29, no. 4, pp. 221–
223, 2004.
[23] E. Giannini, P. Ceppa, F. Botta, et al., “Previous hepatitis
B virus infection is associated with worse disease stage and
occult hepatitis B virus infection has low prevalence and
pathogenicity in hepatitis C virus-positive patients,” Liver
International, vol. 23, no. 1, pp. 12–18, 2003.
[24] J. G. McHutchison, M. Manns, K. Patel, et al., “Adher-
ence to combination therapy enhances sustained response
in genotype-1-infected patients with chronic hepatitis C,”
Gastroenterology, vol. 123, no. 4, pp. 1061–1069, 2002.
[25] M. P. Manns, “Adherence to combination therapy: inﬂu-
ence on sustained virologic response and economic impact,”
Gastroenterology Clinics of North America,v o l .3 3 ,n o .1 ,
supplement 1, pp. 11–24, 2004.
[26] G. Tarantino, P. Conca, P. Sorrentino, and M. Ariello,
“Metabolic factors involved in the therapeutic response of
patients with hepatitis C virus-related chronic hepatitis,”
Journal of Gastroenterology and Hepatology, vol. 21, no. 8, pp.
1266–1268, 2006.
[27] M. Torbenson and D. L. Thomas, “Occult hepatitis B,” Lancet
Infectious Diseases, vol. 2, no. 8, pp. 479–486, 2002.